Clinical potential of circulating free DNA and circulating tumour cells in patients with metastatic non-small-cell lung cancer treated with pembrolizumab.

Mol Oncol · 2021 · PMC8564635 · PMID 34465006

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Additionally, patients with CTCs identified using the CellSearch ® system and high cfDNA levels at baseline showed a trend towards a poorer response to pembrolizumab therapy (Fig.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.